These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24010918)

  • 1. Epidemiology and risk factors for infections in myelodysplastic syndromes.
    Sullivan LR; Sekeres MA; Shrestha NK; Maciejewski JP; Tiu RV; Butler R; Mossad SB
    Transpl Infect Dis; 2013 Dec; 15(6):652-7. PubMed ID: 24010918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infection in the myelodysplastic syndromes.
    Pomeroy C; Oken MM; Rydell RE; Filice GA
    Am J Med; 1991 Mar; 90(3):338-44. PubMed ID: 2003516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database.
    Wilson AB; Neogi T; Prout M; Jick S
    Cancer Epidemiol; 2014 Oct; 38(5):544-9. PubMed ID: 25189344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Lukenbill J; Rybicki L; Sekeres MA; Zaman MO; Copelan A; Haddad H; Fraser T; DiGiorgio MJ; Hanna R; Duong H; Hill B; Kalaycio M; Sobecks R; Bolwell B; Copelan E
    Biol Blood Marrow Transplant; 2013 May; 19(5):720-4. PubMed ID: 23380342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
    Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
    Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
    Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
    Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population.
    Lv L; Lin G; Gao X; Wu C; Dai J; Yang Y; Zou H; Sun H; Gu M; Chen X; Fu H; Bao L
    Am J Hematol; 2011 Feb; 86(2):163-9. PubMed ID: 21264898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
    De Roos AJ; Deeg HJ; Davis S
    Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
    Gonzalez-Porras JR; Cordoba I; Such E; Nomdedeu B; Vallespi T; Carbonell F; Luño E; Ardanaz M; Ramos F; Pedro C; Gomez V; de Paz R; Sanchez-Barba M; Sanz GF; Del Cañizo AC;
    Cancer; 2011 Dec; 117(24):5529-37. PubMed ID: 21638279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune manifestations associated with myelodysplastic syndrome predict a poor prognosis.
    Arinobu Y; Kashiwado Y; Miyawaki K; Ayano M; Kimoto Y; Mitoma H; Akahoshi M; Miyamoto T; Horiuchi T; Akashi K; Niiro H
    Medicine (Baltimore); 2021 Apr; 100(13):e25406. PubMed ID: 33787649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes.
    Yamaguchi N; Ito Y; Ohyashiki K
    Ann Hematol; 2005 Jun; 84(6):383-8. PubMed ID: 15711801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis.
    Adrianzen-Herrera D; Sparks AD; Singh R; Alejos-Castillo D; Batra A; Glushakow-Smith S; Pradhan K; Shastri A; Zakai NA
    Blood Adv; 2023 Nov; 7(22):6913-6922. PubMed ID: 37729616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008.
    McQuilten ZK; Polizzotto MN; Wood EM; Sundararajan V
    Transfusion; 2013 Aug; 53(8):1714-21. PubMed ID: 23305556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.